Kevin Kunzmann

Vogelmeier discusses major changes to the annual COPD report, including a broader threshold for escalating treatment after exacerbation.

Data suggest OSA is an "effect modifier" on the mortality benefit of GLP-1 receptor agonists in patients co-diagnosed with type 2 diabetes.

Halpin reviews the state of triple therapy inhaler prescribing strategies in the era of new biologic options.

Barr discusses the means to encourage systemic adoption of low dose CT scans to help curb the deadliest cancer in the US.

Hanania explains how IL-33 inhibitors including itepekimab and astegolimab may uniquely benefit COPD exacerbation.

2025 data show the US is still failing to adequately identify and initiate care for deadly lung disease. Experts discuss what it will take to turn the tide on this public health issue.

Pitha discusses how ophthalmic drug shortages — more frequent and longer-lasting than the national average — are threatening adherence to glaucoma therapy.

US eye medication shortages make up a sizable share of active drug shortages and last longer, driven by manufacturing issues, weak generics and unclear causes.

Advertisement The US Food and Drug Administration (FDA) has approved Awiqli (insulin icodec-abae) injection 700 units/mL, the first and only

New ADA 2026 analyses show Afrezza delivered comparable glycemic control, favorable safety, and higher treatment satisfaction in youth.